Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part…
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody,…
Oldcastle APG Showcases Complete Product Portfolio at International Builders Show
Leading Provider of Outdoor Living Solutions Launches Flagship Fence Brand, Catalyst Fence…
